Cell line characterization

Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies

Volumn , Issue , 2000, Pages 74-99

  Dusing, Sandra K ^a  

^a BioReliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644633354     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780849398582     Document Type: Chapter

References (37)

1. Center for Biologics Evaluation and Research. Points to Consider in the Characterization of Cell Lines Used to Produce Biologics. Bethesda, MD: US Department of Health and Human Services Food and Drug Administration, 1987.
2. ICH. Topic 5D. Step 3 Draft. Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products. CPMP/ICH/294/95. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1997.
3. ICH. Topic Q5A. Step 4. Consensus Guideline. Quality of Biotechnological Products:Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1997.
4. Center for Biologics Evaluation and Research. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Bethesda, MD:US Department of Health and Human Services Food and Drug Administration, 1997.
5. Center for Biologics Evaluation and Research. Guidance for Industry. Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product. Bethesda, MD: US Department of Health and Human Services Food and Drug Administration, 1999.
6. Center for Biologics Evaluation and Research. Guidance for Industry. Guidance for Human Somatic Cell Therapy and Gene Therapy. Bethesda, MD: US Department of Health and Human Services Food and Drug Administration, 1998.
7. MR Hilleman. Line cell saga-An argument in favor of production of biologics in cancer cells. Adv Exp Biol Med 118:47-58, 1979.
8. R Rustigian, P Johnston, H Reihart. Infection of monkey kidney tissue culture with virus-like agents. Proc Soc Exp Biol Med 88:8-16, 1955.
9. 15, Am J Hyg 63:204-215, 1956.
10. 40. Proc Soc Exp Biol Med 108:420-427, 1960.
11. L Hayflick, PS Moorhead. The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621, 1961.
12. HE Hopps, JC Petricciani, eds. Abnormal Cells, New Products and Risk. Gaithersburg, MD: Tissue Culture Association, 1985.
13. Proceedings, Joint ESACT/IABS Meeting on the Production and Exploitation of Existing and New Animal Cell Substrates. Dev Biol Stand 60, 1985.
14. JC Petricciani. Regulatory considerations for products derived from the new biotechnology. In: Large-Scale Mammalian Cell Culture. New York: Academic Press, 1985, pp 79-86.
15. C Patience, Y Takeuchi, R Weiss. Infection of human cells by an endogenous retrovirus of pigs. Nature Med 3:282-286, 1997.
16. UK National Biological Standards Board. Biological Standardization and Control. The scientific basis of standardization and quality control/safety monitoring of biological substances used in medicine. Geneva, Switzerland: World Health Organization, 1997.
17. RL Garnick. Experience with viral contamination in cell culture. Dev Bioi Stand 88:49-56, 1996.
18. RJ Hay. The seed stock concept and quality control for cell lines. Anal Biochem 171:225-237, 1988.
19. SJ O’Brien, JE Shannon, MH Gail. A molecular approach to the identification and individualization of human and animal cell in culture: Isozyme and allozyme genetic signatures. In Vitro 16:119-135, 1981.
20. RW Nims, AP Shoemaker, MA Bauemschub, LJ Rec, JW Barbell. Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination. In Vitro Cell Dev Bioi 34:35-39, 1998.
21. WP Rowe, JW Hartley, RJ Huebner. Polyoma and other indigenous mouse viruses. In: RC Harris, ed. The Problems of Laboratory Animal Disease. New York: Academic Press, 1962, pp 131-142.
22. A Chang, S Havas, F Borellini, JM Ostrove, RE Bird. A rapid and simple procedure to detect the presence of MVM in conditioned cell fluids or culture media. Biologicals 25:415-419, 1997.
23. SR Adamson. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Dev Bioi Stand 93:89-96, 1998.
24. F Hojman, R Emanoil-Ravier, J Lesser, J Peries. Biological and molecular characterization of an endogenous retrovirus present in CHO/HBs-A Chinese hamster cell line. Dev Bioi Stand 70:195-202, 1998.
25. RA Weiss. Retroviruses produced by hybridomas. N Engl J Med 307:1587, 1982.
26. JA Levy. Mouse plasmacytoma cells produce infectious type C viruses. Lancet II, No. 8348: 522, 1983.
27. WP Rowe, WE Pugh, JW Hartley. Plaque assay techniques for murine leukemia viruses. Virology 5:1136-1139, 1970.
28. PT Peebles. An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C, and the feline-primate viruses RD-114/CCC/M -7. Virology 67:288-291, 1975.
29. DK Haapala, WG Robey, SD Oroszlan, WP Tsai. Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein. J Virol 53:827-833, 1985.
30. MW Cloyd, JW Hartley, WP Rowe. Genetic study of lymphoma induction by AKR mink cell focus-inducing virus in AKR × NFS crosses. J Exp Med 154:450-458, 1981.
31. AS Khan. Retrovirus screening of vaccine cell substrates. Dev Biol Stand 88:157-162, 1996.
32. MA Sommerfelt, RA Weiss. Receptor interference groups of 20 retroviruses plating on human cells. Virology 176:58-69, 1990.
33. PA Nuttall, PD Luther, EJ Stott. Viral contamination of bovine foetal serum and cell cultures. Nature (Lond) 266:835-837, 1977.
34. BJ Potts, M Sawyer, IC Shekarchi, T Wismer, D Huddleston. Peroxidase-labeled primary antibody method for detection of pestivirus contamination in cell cultures. J Virol Meth 26:119-124, 1989.
35. R Schuurman, B van Steenix, A van Strien, J van der Noordaa, C Sol. Frequent detection of bovine polyomavirus in commercial batches of calf serum by using the polymerase chain reaction. J Gen Virol 72:2739-2745, 1991.
36. A Kappeler, C Lutz-Wallace, T Sapp, M Sidhu. Detection of bovine polyoma virus contamination in fetal bovine sera and modified live viral vaccines using polymerase chain reaction. Biologicals 24:131-135, 1996.
37. J Hodgson. Net to help catch NZ serum forgers. Nature Biotechnol 16:505, 1998.